Australian Medical Cannabis News – Medical Cannabis Doctors Australia

Category: Australian Medical Cannabis News

image
10 May

Cannabis Nausea Study Abstract Goals: We measure for the first time how a wide range of cannabis products affect nausea intensity in actual time. Background: Even though the Cannabis plant has been used to treat nausea for millennia, few studies have measured real-time effects of common and commercially available cannabis-based products. Study: Using the Releaf App, 886 […]

Read More
image
09 May

Despite TGA warnings, most Australian medical cannabis patients still access via the black market  The Therapeutic Goods Administration (TGA) is warning consumers about the risks of buying medicinal cannabis products online.  In what seems to be an acknowledgement that the vast majority of medical cannabis patients in Australia still access products via the so-called ‘legacy’ […]

Read More
image
09 May

UK CBD Sales Surge   Research from two industry pressure groups reveals the UK cannabinoid (CBD) industry was worth £690mln in the 12 months to the end of April – up almost a third since a 2019 estimate. CBD is the non-psychoactive element derived from both marijuana and hemp plants. It is used in an […]

Read More
image
02 May

Epidyolex added to PBS for Dravet Syndrome Press conference about a new treatment on the PBS and Phase 2A of the COVID-19 vaccine rollout Read the transcript of the press conference with Minister Hunt at the Star Health GP Respiratory Clinic at the Prahan Townhall in Melbourne on 30 April about a new treatment for […]

Read More
image
12 April

Medical Cannabis: where are we at? This is a fantastic article by respected experts Associate Professor Vicki Kotsirilos AM was Australia’s first authorised GP prescriber of medicinal cannabis in May 2018. Professor Iain S McGregor is the Academic Director of the Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney’s Brain and Mind Centre. […]

Read More
image
12 April

Duration of cannabis impairment New analysis from the Lambert Initiative defines durations of impairment after inhaled or oral THC doses. Findings raise questions about current drug-driving laws, which penalise for THC presence, not intoxication levels. A comprehensive analysis of 80 scientific studies has identified a ‘window of impairment’ of between three and 10 hours caused […]

Read More
image
04 April

Self-Identified Medical Cannabis Consumers Report Substituting It for Prescription Drugs Key Findings • 22% of respondents reported that medical cannabis has decreased pain (517 respondents, N=2,302).a • 39% reported that medical cannabis has improved quality of life (900 respondents, N=2,302). • 61% reported having replaced prescription opioids and benzodiazepines with medical cannabis (988 respondents, N=1,622). […]

Read More
image
04 April

Cannabis tolerance can decrease impairment in medical cannabis consumers   Previous studies have reported conflicting results in terms of acute effects of cannabis in man. Independently of other factors, such discrepancy may be attributable to the different cannabis use history of study volunteers. It is thought that regular cannabis users may develop tolerance to the […]

Read More
image
04 March

To date, the TGA has approved SAS applications including, but not limited to, the following indications: chemotherapy-induced nausea and vomiting refractory paediatric epilepsy palliative care indications cancer pain neuropathic pain spasticity from neurological conditions anorexia and wasting associated with chronic illness (such as cancer). The above list is provided as an overview and does not […]

Read More
image
25 February

CSIRO to research medical cannabis The CSIRO has secured a license to develop new medicinal cannabis products in Australia. It’s been branded a significant development for those with a variety of conditions including multiple sclerosis and chronic pain. Australia’s national science agency will play a “pivotal role” in removing the stigma of cannabis, according to […]

Read More